1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine has been researched along with tg 003 in 1 studies
| Studies (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Trials (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Recent Studies (post-2010) (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Studies (tg 003) | Trials (tg 003) | Recent Studies (post-2010) (tg 003) |
|---|---|---|---|---|---|
| 9 | 0 | 2 | 45 | 0 | 33 |
| Protein | Taxonomy | 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine (IC50) | tg 003 (IC50) |
|---|---|---|---|
| Dual specificity protein kinase CLK2 | Mus musculus (house mouse) | 0.2 | |
| Dual specificity protein kinase CLK4 | Mus musculus (house mouse) | 0.015 | |
| Dual specificity protein kinase CLK1 | Mus musculus (house mouse) | 0.02 | |
| Dual specificity protein kinase CLK1 | Homo sapiens (human) | 0.064 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | 0.6172 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Mus musculus (house mouse) | 0.012 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
1 other study(ies) available for 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine and tg 003
| Article | Year |
|---|---|
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |